FDA recalls NAD+ powder due to failed reconstitution
Olympia Compounding Pharmacy is recalling NAD+ powder vials nationwide because they fail to reconstitute properly. Affected lot F41116 has a beyond-use date of 6/16/2022.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA classified this as Class II, indicating a serious adverse health consequence is possible. Failed reconstitution prevents proper preparation and use of the medication, constituting a risk-of-harm product. No illnesses or injuries are reported.
Plain-English summary
Olympia Compounding Pharmacy is recalling NAD+ Nicotinamide Adenine Dinucleotide lyophilized powder for reconstitution distributed nationwide. The product is supplied as a 500 mg multi-dose vial.
The manufacturer initiated the recall due to failed reconstitution time. The specific lot affected is F41116, which has a beyond-use date of 6/16/2022.
Healthcare providers and patients who received vials from this lot should contact their dispensing pharmacy or healthcare provider regarding this recall.
The recalled product
- Product
- NAD+ Nicotinamide Adenine Dinucleotide Lyophilized powder for reconstitution, Multi-Dose 500 mg Per Vial, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0083-00
- Category
- Drug — Compounded Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: F41116 BUD: 6/16/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 34 recalled by Olympia Compounding Pharmacy dba Olympia Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 34 products in this recall →Related recalls
Same manufacturer · Olympia Compounding Pharmacy dba Olympia Pharmacy
See all →- HighLidocaine 2% injectable solution recalled for lack of sterility assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Compounded Papaverine Injection Due to Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Testosterone Cypionate Injection Vials for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighCompounded pharmaceutical vials recalled due to sterility assurance failure
FDA (Drugs) · 2022-06-01
- HighOndansetron Hydrochloride vials recalled due to sterility assurance concerns
FDA (Drugs) · 2022-06-01
Same hazard · reconstitution failure
See all →- SevereSincalide Injection Recalled for Potency and Reconstitution Issues
FDA (Drugs) · 2022-03-30